The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next ...

The FDA, in a Wednesday legal filing, said that its much-anticipated review of the abortion drug mifepristone won’t be ...

A court-ordered status update said the agency does not plan to implement any restrictions while its review of the pill ...

The FDA faces a court-ordered deadline today to update a federal judge in Louisiana on the status of its ongoing review of the abortion drug mifepristone, potentially shedding light on a secretive ...

A federal judge in Louisiana ordered the agency to provide an update on its safety study as part of a lawsuit seeking to ...

Pro-life disillusionment with President Trump's second-term record worsens GOP voter enthusiasm gap going into the midterms. ...

The FDA says its ongoing safety review​ of the nation's main abortion pill​ will continue into next year, a timeline quickly condemned by abortion rights foes hoping to see the drug's use curtailed.

Three Republican-led US states are testing a novel legal argument as they seek to stem the flow of abortion pills to residents who can still obtain them from out-of-state providers despite their ...

The U.S. Food and Drug Administration said late Wednesday that it expects to complete its long-awaited safety review of abortion pills by mid-December and issue a report evaluating the results by ...

The administration is delaying this report because attacks on medication abortion will backfire with voters, but extremists will try to ban abortion as soon as the election is over.” ...

Anti-abortion groups plan to urge states to require ultrasounds, waiting periods and in-person visits for abortion pills as ...